The CDK4/6 inhibitor ribociclib has shown a survival benefit in younger women with advanced breast cancer, according to trial findings presented at ASCO 2019. When added to standard endocrine therapy in premenopausal women with advanced hormone receptor positive cancer, ribociclib was associated with a significant improvement in overall survival rates compared to endocrine therapy alone, ...
Ribociclib improves survival in younger women with advanced breast cancer
By Michael Woodhead
2 Jun 2019